{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:59Z","timestamp":1790740619634,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,1]]},"DOI":"10.1097\/qad.0b013e32832b4377","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T11:23:27Z","timestamp":1242905007000},"page":"1109-1118","source":"Crossref","is-referenced-by-count":207,"title":["Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment"],"prefix":"10.1097","volume":"23","author":[{"given":"Richard H","family":"Haubrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A","family":"Riddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Gregory","family":"DiRienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Komarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Powderly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Klingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Garren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane V","family":"Havlir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/317429","article-title":"Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group","volume":"31","author":"Dube","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1086\/507333","article-title":"Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy","volume":"43","author":"Wohl","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case\u2013control study","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0b013e318031d5a0","article-title":"Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)","volume":"44","author":"Shikuma","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.qai.0000137001.40505.56","article-title":"Pharmacokinetic properties of nucleoside\/nucleotide reverse transcriptase inhibitors","volume":"37","author":"Piliero","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384","volume":"45","author":"Dube","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1086\/429697","article-title":"In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA","volume":"191","author":"Mallon","year":"2005","journal-title":"J Infect Dis"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","article-title":"Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level","volume":"8","author":"Nolan","year":"2003","journal-title":"Antivir Ther"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","article-title":"Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes \u2013 a 96-week analysis","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1310\/WRL8-DWH1-7VQL-AK81","article-title":"Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy","volume":"4","author":"Smith","year":"2003","journal-title":"HIV Clin Trials"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200906010-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:32Z","timestamp":1786038452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200906010-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,1]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832b4377","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6,1]]}}}